Stryker names Spencer Stiles CEO while Stifel cuts target for Stryker stock

Published on 10/06/2026 at 17:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stifel sets USD 330 for Stryker stock versus USD 360. Spencer Stiles becomes CEO on January 1, 2027 after the October 6, 2026 announcement.

Isometrische Illustration der Wertschöpfungskette von Rohstoff bis Operationssaal — Isometrische 3D-Grafik zeigt die Wertschöpfungskette der Medizintechnik-Branche, in der Stryker Corp. US8636671013 tätig ist, Illustration mit AI erstellt.

Stryker Corp. (US8636671013) will appoint Spencer Stiles chief executive officer on January 1, 2027, while Kevin Lobo moves to executive chair, according to GlobeNewswire on October 6, 2026. The same day, Stryker stock had a market capitalization of USD 107.8 billion, while the NYSE quote stood at USD 281.12 at 11:01 a.m. ET.

Succession sets the 2027 test

Stiles currently serves as Stryker's president and chief operating officer and will join the board when he becomes CEO. Lobo will remain CEO through December 31, 2026, creating a defined handover rather than an immediate management break, according to GlobeNewswire on October 6, 2026.

The timing places the leadership change between the second-quarter report and the next scheduled results. Stryker will discuss third-quarter 2026 results during a webcast on October 29, 2026, at 4:30 p.m. ET, according to GlobeNewswire.

Analyst target reflects pressure

Stifel lowered its Stryker price target to USD 330 from USD 360 on September 29, 2026, while maintaining a Buy rating, according to Investing.com. The firm reduced its 2026 organic revenue growth estimate to 8.30 percent from 8.60 percent and placed it at the low end of Stryker's 8.30 percent to 9.30 percent company outlook.

The latest reported quarter gives the transition a measurable operating baseline. Stryker recorded USD 6.59 billion of revenue in the second quarter of 2026, up 9.40 percent from the same quarter a year earlier, while adjusted earnings per share reached USD 3.69 versus consensus of USD 3.49, according to MarketBeat on September 15, 2026.

NYSE valuation stays below the high

Stryker's USD 281.12 NYSE quote on October 6, 2026 stood 28.39 percent below the 52-week high of USD 392.55 and above the 52-week low of USD 267.00. For investors, the October 29 results will provide the next quantified test of the growth outlook and the incoming CEO's operating continuity.